Loading
Led the Chinese trials of PD-1 blockade in nasopharyngeal and lung cancer and the early studies of the EGFR×HER3 bispecific ADC iza-bren.
Li Zhang is Professor of Medical Oncology and Director of the Department of Medical Oncology at Sun Yat-sen University Cancer Center in Guangzhou. He led the Chinese trials of PD-1 blockade with camrelizumab and toripalimab in nasopharyngeal carcinoma and lung cancer, and the early-phase studies of izalontamab brengitecan, the EGFR and HER3 bispecific antibody-drug conjugate from SystImmune and Sichuan Biokin, in non-small-cell lung cancer and nasopharyngeal carcinoma. His publications include the CAPTAIN-1st trial of camrelizumab added to gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. His interests are lung cancer, nasopharyngeal carcinoma, immunotherapy and antibody-drug conjugates.
Shares HARMONi-A, Sun Yat-sen University Cancer Center, Camrelizumab, Head and neck squamous cell carcinoma.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.